npj Precision Oncology (Oct 2022)

MatchMiner: an open-source platform for cancer precision medicine

  • Harry Klein,
  • Tali Mazor,
  • Ethan Siegel,
  • Pavel Trukhanov,
  • Andrea Ovalle,
  • Catherine Del Vecchio Fitz,
  • Zachary Zwiesler,
  • Priti Kumari,
  • Bernd Van Der Veen,
  • Eric Marriott,
  • Jason Hansel,
  • Joyce Yu,
  • Adem Albayrak,
  • Susan Barry,
  • Rachel B. Keller,
  • Laura E. MacConaill,
  • Neal Lindeman,
  • Bruce E. Johnson,
  • Barrett J. Rollins,
  • Khanh T. Do,
  • Brian Beardslee,
  • Geoffrey Shapiro,
  • Suzanne Hector-Barry,
  • John Methot,
  • Lynette Sholl,
  • James Lindsay,
  • Michael J. Hassett,
  • Ethan Cerami

DOI
https://doi.org/10.1038/s41698-022-00312-5
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Widespread, comprehensive sequencing of patient tumors has facilitated the usage of precision medicine (PM) drugs to target specific genomic alterations. Therapeutic clinical trials are necessary to test new PM drugs to advance precision medicine, however, the abundance of patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to PM trials. To facilitate enrollment onto PM trials, we developed MatchMiner, an open-source platform to computationally match genomically profiled cancer patients to PM trials. Here, we describe MatchMiner’s capabilities, outline its deployment at Dana-Farber Cancer Institute (DFCI), and characterize its impact on PM trial enrollment. MatchMiner’s primary goals are to facilitate PM trial options for all patients and accelerate trial enrollment onto PM trials. MatchMiner can help clinicians find trial options for an individual patient or provide trial teams with candidate patients matching their trial’s eligibility criteria. From March 2016 through March 2021, we curated 354 PM trials containing a broad range of genomic and clinical eligibility criteria and MatchMiner facilitated 166 trial consents (MatchMiner consents, MMC) for 159 patients. To quantify MatchMiner’s impact on trial consent, we measured time from genomic sequencing report date to trial consent date for the 166 MMC compared to trial consents not facilitated by MatchMiner (non-MMC). We found MMC consented to trials 55 days (22%) earlier than non-MMC. MatchMiner has enabled our clinicians to match patients to PM trials and accelerated the trial enrollment process.